Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Zilli

Showing results (221-230 of 235) with videos related to

Pageof 24
Sort By:
European Urology Focus|January 2, 2021
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer MetastasesThomas Zilli, Piet Dirix, Reino Heikkilä, et al.
European Urology Oncology|October 11, 2023
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 TrialPiet Ost, Shankar Siva, Sigmund Brabrand, et al.
European Urology|July 24, 2019
Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal RadiotherapyElise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al.
The Lancet. Oncology|March 1, 2023
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortiumStephanie G C Kroeze, Matea Pavic, Karin Stellamans, et al.
Cancer Treatment Reviews|May 9, 2021
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensusBarbara A Jereczek-Fossa, Giulia Marvaso, Mattia Zaffaroni, et al.
International Journal of Radiation Oncology, Biology, Physics|January 3, 2023
Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International ConsensusSimon K B Spohn, Cédric Draulans, Amar U Kishan, et al.
The Lancet. Oncology|April 30, 2026
Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortiumJoachim Widder, Guus M Bol, Inga-Malin Simek, et al.
World Journal of Urology|September 19, 2024
Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic reviewErnest Kaufmann, Stefanie Aeppli, Winfried Arnold, et al.
The Lancet. Oncology|May 2, 2024
Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of UrologyGiulia Marvaso, Barbara Alicja Jereczek-Fossa, Mattia Zaffaroni, et al.
Bladder Cancer (Amsterdam, Netherlands)|January 19, 2026
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancerErnest Kaufmann, Stefanie Aeppli, Andres Affentranger, et al.
Pageof 24

Showing results (221-230 of 235) with videos related to

Sort By:
Pageof 24
European Urology Focus|January 2, 2021
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer MetastasesThomas Zilli, Piet Dirix, Reino Heikkilä, et al.
European Urology Oncology|October 11, 2023
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 TrialPiet Ost, Shankar Siva, Sigmund Brabrand, et al.
European Urology|July 24, 2019
Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal RadiotherapyElise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al.
The Lancet. Oncology|March 1, 2023
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortiumStephanie G C Kroeze, Matea Pavic, Karin Stellamans, et al.
Cancer Treatment Reviews|May 9, 2021
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensusBarbara A Jereczek-Fossa, Giulia Marvaso, Mattia Zaffaroni, et al.
International Journal of Radiation Oncology, Biology, Physics|January 3, 2023
Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International ConsensusSimon K B Spohn, Cédric Draulans, Amar U Kishan, et al.
The Lancet. Oncology|April 30, 2026
Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortiumJoachim Widder, Guus M Bol, Inga-Malin Simek, et al.
World Journal of Urology|September 19, 2024
Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic reviewErnest Kaufmann, Stefanie Aeppli, Winfried Arnold, et al.
The Lancet. Oncology|May 2, 2024
Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of UrologyGiulia Marvaso, Barbara Alicja Jereczek-Fossa, Mattia Zaffaroni, et al.
Bladder Cancer (Amsterdam, Netherlands)|January 19, 2026
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancerErnest Kaufmann, Stefanie Aeppli, Andres Affentranger, et al.
Pageof 24